Evoke Pharma, Inc. - Common Stock (EVOK)

Let's have a look at the stocks with an unusual volume in today's session.

Evoke Pharma surges after QOL Medical announces $11 cash acquisition, a 140% premium, expected to close by the end of 2025.

As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

The US market regular session of Thursday is over, let's have a look at the top gainers and losers in the after hours session today.

As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Healthcare stocks SNOA, EVOK, KALA, DNA, & SNGX soar with massive momentum gains, signaling breakout potential in biotech & pharma.

The newly allowed patent covers the use of Gimoti in patients with moderate to severe gastroparesis and is expected to extend market exclusivity through 2036.

Shares of Evoke Pharma are trading sharply higher Wednesday morning. The specialty pharma company received a U.S. Patent Office Notice of Allowance for a new patent on its lead product, GIMOTI.